Lu Jianlei, Zhong Feng, Sun Beibei, Wang Chao
Department of Surgical Urology, Affiliated Hospital to Academy of Medical Sciences.
Department of Surgical Urology, First People's Hospital.
Medicine (Baltimore). 2019 Aug;98(35):e16576. doi: 10.1097/MD.0000000000016576.
G protein-coupled receptor 137 (GPR137) was reported to be associated with several cancers, but its role in bladder cancer has not been reported. The purpose of this study was to evaluate clinical significance of GPR137 in bladder cancer.
The expressions of GPR137 in pathological tissues and corresponding normal tissues from bladder cancer patients were detected via quantitative real time polymerase chain reaction (qRT-PCR). Western blot was performed to detect GPR137 expression in bladder cancer tissues and adjacent normal tissues. Chi-Squared test analyzed the relationship between GPR137 expression and clinical features of bladder cancer patients. Additionally, Kaplan-Meier method was adopted in estimating overall survival of bladder cancer patients. Prognostic value of GPR137 was evaluated through Cox regression analysis.
The expression of GPR137 mRNA and protein in pathological tissues was significantly higher than that in adjacent normal tissues (P < .001). Moreover, similar result was found for bladder cancer patients and healthy controls (P < .001). And GPR137 expression was associated with tumor size (P = .006) and TNM stage (P = .012). The results of Kaplan-Meier analysis suggested that patients with high expression of GPR137 had shorter overall survival time than those with low expression (Log rank test, P = .001). Cox regression analysis indicated that GPR137 could act as an independent biomarker for bladder cancer prognosis (HR = 1.850, 95% CI = 1.272-2.689, P = .001).
Abnormal expression of GPR137 is associated with bladder cancer and GPR137 is a potential biomarker for the therapy and prognosis of bladder cancer.
据报道，G蛋白偶联受体137（GPR137）与多种癌症相关，但其在膀胱癌中的作用尚未见报道。本研究旨在评估GPR137在膀胱癌中的临床意义。
通过定量实时聚合酶链反应（qRT-PCR）检测膀胱癌患者病理组织及相应正常组织中GPR137的表达。采用蛋白质免疫印迹法检测膀胱癌组织及癌旁正常组织中GPR137的表达。采用卡方检验分析GPR137表达与膀胱癌患者临床特征之间的关系。此外，采用Kaplan-Meier法评估膀胱癌患者的总生存期。通过Cox回归分析评估GPR137的预后价值。
病理组织中GPR137 mRNA和蛋白的表达明显高于癌旁正常组织（P<0.001）。此外，在膀胱癌患者和健康对照中也发现了类似结果（P<0.001）。GPR137表达与肿瘤大小（P=0.006）和TNM分期（P=0.012）相关。Kaplan-Meier分析结果表明，GPR137高表达患者的总生存时间短于低表达患者（对数秩检验，P=0.001）。Cox回归分析表明，GPR137可作为膀胱癌预后的独立生物标志物（HR=1.850，95%CI=1.272-2.689；P=0.001）。
GPR137的异常表达与膀胱癌相关，GPR137是膀胱癌治疗和预后的潜在生物标志物。
